title: Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database.
abstract: BACKGROUND
  We sought to compare mortality rates and related diagnoses in hospitalized patients with multiple sclerosis (MS), those with diabetes mellitus (DM), and the general hospitalized population (GHP).
  
  
  METHODS
  Patients who died between 2007 and 2011 were identified in the US hospital-based Premier Healthcare Database. Demographic information was collected, mortality rates calculated, and principal diagnoses categorized.
  
  
  RESULTS
  Of 55,152 unique patients with MS identified, 1518 died. Mean age at death was 10 years younger for the MS group (63.4 years) than for the DM (73.3 years) and GHP (73.1 years) groups. Age-adjusted mortality rates, based on the 2000 US Standard Million Population, were 1077, 1248, and 1133 per 100,000, respectively. Infection was the most common principal diagnosis at the hospital stay during which the patient died in the MS cohort (43.1% vs. 26.3% and 24.0% in the DM and GHP groups, respectively). Other common principal diagnoses in the MS group included pulmonary (17.5%) and cardiovascular (12.1%) disease. Septicemia/sepsis/septic shock was a secondary diagnosis for 50.7% of patients with MS versus 36.0% and 31.0% of patients in the DM and GHP cohorts, respectively.
  
  
  CONCLUSIONS
  Patients with MS had a shorter life span than patients with DM or the GHP and were more likely to have a principal diagnosis of infection at their final hospital stay. However, the database was limited to codes recorded in the hospital; diagnoses received outside the hospital were not captured.
authors.affiliation: Premier Healthcare Solutions Inc, Charlotte, NC, USA (FRE); Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA (JP); University of Alabama School of Public Health, Birmingham, AL, USA (GC); Slone Epidemiology Center at Boston University, Boston, MA, USA (DWK); and Myelo Pharmaceuticals GmbH, Berlin, Germany (DP). Dr. Ernst is now with Indegene Inc, Kennesaw, GA, USA.
authors.forename: Frank R
authors.initials: FR
authors.lastname: Ernst
authors.affiliation: Premier Healthcare Solutions Inc, Charlotte, NC, USA (FRE); Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA (JP); University of Alabama School of Public Health, Birmingham, AL, USA (GC); Slone Epidemiology Center at Boston University, Boston, MA, USA (DWK); and Myelo Pharmaceuticals GmbH, Berlin, Germany (DP). Dr. Ernst is now with Indegene Inc, Kennesaw, GA, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Pocoski
authors.affiliation: Premier Healthcare Solutions Inc, Charlotte, NC, USA (FRE); Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA (JP); University of Alabama School of Public Health, Birmingham, AL, USA (GC); Slone Epidemiology Center at Boston University, Boston, MA, USA (DWK); and Myelo Pharmaceuticals GmbH, Berlin, Germany (DP). Dr. Ernst is now with Indegene Inc, Kennesaw, GA, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Cutter
authors.affiliation: Premier Healthcare Solutions Inc, Charlotte, NC, USA (FRE); Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA (JP); University of Alabama School of Public Health, Birmingham, AL, USA (GC); Slone Epidemiology Center at Boston University, Boston, MA, USA (DWK); and Myelo Pharmaceuticals GmbH, Berlin, Germany (DP). Dr. Ernst is now with Indegene Inc, Kennesaw, GA, USA.
authors.forename: David W
authors.initials: DW
authors.lastname: Kaufman
authors.affiliation: Premier Healthcare Solutions Inc, Charlotte, NC, USA (FRE); Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA (JP); University of Alabama School of Public Health, Birmingham, AL, USA (GC); Slone Epidemiology Center at Boston University, Boston, MA, USA (DWK); and Myelo Pharmaceuticals GmbH, Berlin, Germany (DP). Dr. Ernst is now with Indegene Inc, Kennesaw, GA, USA.
authors.forename: Dirk
authors.initials: D
authors.lastname: Pleimes